The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future

被引：40
作者：
Allegretti, Jessica [1 ,2 ]
Eysenbach, Lindsay M. [3 ,4 ]
El-Nachef, Najwa [5 ]
Fischer, Monika [6 ]
Kelly, Colleen [7 ,8 ]
Kassam, Zain [2 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA
[3] OpenBiome, Somerville, MA USA
[4] Yale Univ, Sch Med, New Haven, CT USA
[5] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA
[6] Indiana Univ Sch Med, Dept Med, Div Gastroenterol, Indianapolis, IN 46202 USA
[7] Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI USA
[8] Lifespan Hosp Syst, Providence, RI USA
来源：
INFLAMMATORY BOWEL DISEASES | 2017年 / 23卷 / 10期
关键词：
inflammatory bowel disease; fecal microbiota transplantation; ulcerative colitis; Crohn's disease; microbiome; CLOSTRIDIUM-DIFFICILE INFECTION; ACTIVE ULCERATIVE-COLITIS; REMISSION; VANCOMYCIN; RECURRENT; EPIDEMIOLOGY; PREVALENCE; DIARRHEA; SUCCESS; SOCIETY;
D O I：
10.1097/MIB.0000000000001247
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Fecal microbiota transplantation (FMT) has changed the standard of care for Clostridium difficile infection. However, there is limited data focusing on efficacy and safety profile of FMT in patients with C. difficile infection with underlying inflammatory bowel disease (IBD), including the risk of IBD flare. Recently, there is also emerging evidence supporting the role of FMT to treat IBD including promising randomized trials in ulcerative colitis. However, with heterogeneity across these studies, the clinical application of this emerging therapy has yet to be fully elucidated. Here, we aim to review the current landscape of this rapidly developing field, mapping the efficacy and safety of FMT (1) to treat C. difficile infection in patients with IBD, (2) to treat underlying IBD, and (3) outline ongoing clinical trials and the future of the microbiome space.
引用
收藏
页码：1710 / 1717
页数：8
相关论文
共 42 条
[1]   Clostridium difficile infection: epidemiology, risk factors and management [J].
Ananthakrishnan, Ashwin N. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (01) :17-26
[2]  
Ananthakrishnan AN, 2010, EXPERT REV GASTROENT, V4, P589, DOI [10.1586/egh.10.55, 10.1586/EGH.10.55]
[3]  
Bajaj J, 2017, J HEPATOL, V66, pS448
[4]  
Binion David G, 2012, Gastroenterol Hepatol (N Y), V8, P615
[5]   Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection [J].
Cammarota, G. ;
Masucci, L. ;
Ianiro, G. ;
Bibbo, S. ;
Dinoi, G. ;
Costamagna, G. ;
Sanguinetti, M. ;
Gasbarrini, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (09) :835-843
[6]   Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection A Systematic Review [J].
Cammarota, Giovanni ;
Ianiro, Gianluca ;
Gasbarrini, Antonio .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (08) :693-702
[7]   Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Single-Center Experience [J].
Chin, Samantha M. ;
Sauk, Jenny ;
Mahabamunuge, Jasmine ;
Kaplan, Jess L. ;
Hohmann, Elizabeth L. ;
Khalili, Hamed .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (04) :597-599
[8]   Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations [J].
Chu, Nathaniel D. ;
Smith, Mark B. ;
Perrotta, Allison R. ;
Kassam, Zain ;
Alm, Eric J. .
PLOS ONE, 2017, 12 (01)
[9]   Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [J].
Cohen, Stuart H. ;
Gerding, Dale N. ;
Johnson, Stuart ;
Kelly, Ciaran P. ;
Loo, Vivian G. ;
McDonald, L. Clifford ;
Pepin, Jacques ;
Wilcox, Mark H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) :431-455
[10]  
Costello S, 2017, J CROHNS COLITIS
12345